bit.bio
Cambridge, England, United Kingdom · Financial Services, Information Technology, Payments
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at a
Key facts
- Headquarters
- Cambridge, England, United Kingdom
- Employees
- 162
- Industries
- Financial Services, Information Technology, Payments
- Status
- Private
- Website
- www.bit.bio
- Company page
Recent activity at bit.bio
- : Human cell programming company bit.bio closes $25M Series D funding to enhance its cell models and increase technology access. The investment includes support from M&G Investments and Dr Jonathan Milner.
- : bit.bio Appoints Sejla Salic-Hainzl as Chief Technology Officer
- : Bit.bio raises $50 million in a funding round led by M&G, who invested $32 million. The funds will help expand global operations and develop new products.
- : UK cell therapy biotech bit.bio pivots to tool development, forms partnership with BlueRock Therapeutics (date Fundz recorded it)
- : bit.bio Introduces ioTracker Cells Range to Enhance Neurodegenerative Disease Research at SLAS 2025.
- : bit.bio Successfully Defends Patent for opti-ox™ Cell Programming Technology to Enhance Pluripotent Stem Cell Applications
- : bit.bio Appoints Przemek Obloj as Chief Financial Officer
- : Bit.Bio Raises In Excess Of $100 Million In First Close Of Series B Financing
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
bit.bio funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2026 | Series D | $25.0M |
| Jan 2026 | Funding Round | $50.0M |
| Nov 2021 | Series B | Undisclosed |
Leadership
- Sejla Salic-Hainzl, Chief Technology Officer
- Connie O'Donnell, Director of Marketing
- Abbey Crawford, Marketing Operations Manager
- Przemek Obloj, Chief Executive Officer
Verified email and direct lines for bit.bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
bit.bio files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
bit.bio in the news
- Human cell programming company bit.bio closes $25M Series D - Tech.eu (Nov 04, 2026)
- How Human iPSCs are Revolutionizing Drug Discovery in 2027 - BioInformant (Oct 06, 2026)
- Cambridge biotech bit.bio raises $25m Series D funding to scale human cell models - Business Weekly (Nov 03, 2026)
- Business for bit.bio CEO Dr Emma Pepperell can appear to an external observer to be as straightforward as ABC - Business Weekly (Jul 12, 2026)
- M&G leads $50m funding round for Cambridge bio spinout - The Times (Jan 09, 2026)
- bit.bio raises $30 million led by M&G Investments - News-Medical (Dec 18, 2024)
- bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology - BioSpace (Oct 16, 2024)
- bit.bio expands on back of lower prices and broader distribution model - Business Weekly (Feb 22, 2026)
Companies similar to bit.bio
- Token.io · Financial Services, Information Technology, Payments, Software
- Helios · Financial Services, Information Technology, Payments, Software
- Nucleus Security · Financial Services, Information Technology, Payments, Software
- Cloud Walk · Financial Services, Information Technology, Payments, Software
- AllPaid · Financial Services, Information Technology, Payments, Software
About bit.bio: questions and answers
What does bit.bio do?
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at a
Where is bit.bio headquartered?
bit.bio is headquartered in Cambridge, England, United Kingdom.
How many employees does bit.bio have?
bit.bio has about 162 employees.
Has bit.bio raised funding?
Yes. Fundz has recorded 3 funding events for bit.bio. The most recent, Series D of $25.0M, was in Nov 2026.
Who leads bit.bio?
Przemek Obloj is a Chief Executive Officer at bit.bio.
What is the latest news on bit.bio?
On Nov 4, 2026, Human cell programming company bit.bio closes $25M Series D funding to enhance its cell models and increase technology access. The investment includes support from M&G Investments and Dr Jonathan Milner.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy